Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform Utilization

        

TARPON SPRINGS, Fla., July 15, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor, today announced the signing of a new commercial agreement with a non-disclosed EU-based biotechnology company. The agreement provides the partner with a non-exclusive global license to a range of selected proprietary Allarity DRP^® algorithms in breast cancer, alongside laboratory services from Allarity’s Medical Laboratory in Denmark.

Read more at globenewswire.com